title: Tumor responsiveness to statins requires overexpression of the ARF6 pathway.
abstract: The mevalonate pathway results in the prenylation of small GTPases, which are pivotal for oncogenesis and cancer malignancies. However, inhibitors of this pathway, such as statins, have not necessarily produced favorable results in clinical trials. We recently identified properties of statin responders, together with the underlying molecular mechanisms and simple biomarkers to predict these responders.
authors.affiliation: Department of Molecular Biology, Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.
authors.forename: Hisataka
authors.initials: H
authors.lastname: Sabe
authors.affiliation: Department of Molecular Biology, Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.
authors.forename: Ari
authors.initials: A
authors.lastname: Hashimoto
authors.affiliation: Department of Molecular Biology, Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hashimoto
authors.affiliation: Department of Molecular Biology, Graduate School of Medicine, Hokkaido University , Sapporo, Hokkaido, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Oikawa
keywords: ARF6; cancer therapeutics; drug resistance; mevalonate pathway; statin